Viveve Medical (VIVE) 10-Q 11 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 10, 2017
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vivmf
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		19,354,586
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	[1]
Current assets:
Cash and cash equivalents	$ 31,389	$ 8,086
Accounts receivable	4,020	2,091
Inventory	2,383	2,687
Prepaid expenses and other current assets	1,240	1,066
Total current assets	39,032	13,930
Property and equipment, net	791	483
Other assets	152	136
Total assets	39,975	14,549
Current liabilities:
Accounts payable	3,359	3,086
Accrued liabilities	2,087	2,186
Note payable, current portion	2,870	1,867
Total current liabilities	8,316	7,139
Note payable, noncurrent portion	6,794	7,762
Other noncurrent liabilities	90	53
Total liabilities	15,200	14,954
Commitments and contingences (Note 7)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2017 and December 31, 2016; no shares issued
Common stock, $0.0001 par value; 75,000,000 shares authorized as of March 31, 2017 and December 31, 2016; 19,346,856 and 10,661,201 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	2	1
Additional paid-in capital	100,090	68,216
Accumulated deficit	(75,317)	(68,622)
Total stockholders’ equity (deficit)	24,775	(405)
Total liabilities and stockholders’ equity (deficit)	$ 39,975	$ 14,549
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	19,346,856	10,661,201
Common stock, shares outstanding (in shares)	19,346,856	10,661,201

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue	$ 3,041	$ 1,284
Cost of revenue	1,619	936
Gross profit	1,422	348
Operating expenses:
Research and development	2,388	1,796
Selling, general and administrative	5,450	2,548
Total operating expenses	7,838	4,344
Loss from operations	(6,416)	(3,996)
Interest expense, net	(263)	(108)
Other expense, net	(16)	(2)
Comprehensive and net loss	$ (6,695)	$ (4,106)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.57)	$ (0.55)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	11,663,765	7,493,011

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017		Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (6,695)		$ (4,106)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	107		21
Stock-based compensation	372		188
Fair value of warrants issued			142
Non-cash interest expense	35		45
Changes in assets and liabilities:
Accounts receivable	(1,929)		(198)
Inventory	40		623
Prepaid expenses and other current assets	(174)		(314)
Other noncurrent assets	(16)		(8)
Accounts payable	273		197
Accrued and other liabilities	(62)		1,361
Net cash used in operating activities	(8,049)		(2,049)
Cash flows from investing activities:
Purchase of property and equipment	(151)		(36)
Net cash used in investing activities	(151)		(36)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	31,503
Transaction costs in connection with November 2015 Offering			(3)
Repayments of note payable			(299)
Proceeds from exercise of warrant			27
Proceeds from exercise of stock option			6
Net cash provided by (used in) financing activities	31,503		(269)
Net increase (decrease) in cash and cash equivalents	23,303		(2,354)
Cash and cash equivalents - beginning of period	8,086	[1]	7,360
Cash and cash equivalents - end of period	31,389		5,006
Supplemental disclosure:
Cash paid for interest	194		64
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Restricted stock awards granted to employees for 2015 accrued bonuses			246
Net transfer of equipment between inventory and property and equipment	$ 264
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry in some countries by marketing Geneveve™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity. Public Offering On March 22, 2017, “March 2017 8,625,000 $4.00 $34,500,000. $31,503,000. March 2017 12 On June 17, 2016, “June 2016 3,105,000 $5.00 $15,525,000. $13,886,000. Change of Corporate Domicile On May 9, 2016, May 10, 2016, $0.0001 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2016, February 16, 2017. three March 31, 2017 December 31, 2017

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products likely require clearance or approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required clearances or approvals or for the indications requested. If the Company was denied such clearances or approvals or if such clearances or approvals were delayed, it would have a material adverse effect on the Company’s financial results, financial position and future cash flows. The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval that it refers to as Geneveve™. Geneveve includes three third In the U.S., the Company sells its products primarily through a direct sales force to health care practitioners. Outside the U.S., the Company sells through an extensive network of distribution partners. During the three March 31, 2017, two 33% three March 31, 2016, three 86% 10% three March 31, 2017 2016. Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not provide its customers with a right of return. Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Product Warranty The Company’s products are generally subject to a one Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2017 2016, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2017 2016 Stock options to purchase common stock 2,134,214 1,131,768 Warrants to purchase common stock 425,274 401,446 Restricted common stock awards 12,500 - Recently Issued and Adopted Accounting Standards In May 2014, 2014 09, 606).” five December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 2015 14); 2016 08); 2016 10); 2016 10). May 2016, 2016 12, 606) May 2014. In July 2015, 2015 11, 2015 11”). 2015 11 first 2015 11 January 1, 2017 January 1, 2017, In February 2016, 2016 02, 842)”. December 15, 2018, In March 2016, 2016 09, 718): December 15, 2016, January 1, 2017 In August 2016, 2016 15, 230)”. zero December 15, 2017, We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 Level 2 Pricing is provided by third Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no financial instruments that were measured at fair value on a recurring basis as of March 31, 2017 December 31, 2016. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 31, 2017 December 31, 2016

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued liabilities consisted of the following (in thousands): March 31, December 31, 2017 2016 Accrued professional fees $ 1,026 $ 483 Accrued bonuses 275 1,102 Accrued payroll and other related expenses 364 389 Accrued sales and use tax 111 39 Accrued interest 67 65 Other accruals 244 108 Total accrued liabilities $ 2,087 $ 2,186

Note 5 - Note Payable

Note 5 - Note Payable	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	5. On June 20, 2016, January 13, 2017 “2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. July 1, 2017 30 30 6.96%, 7.40%. 7.94% March 31, 2017. In connection with the 2016 10 100,402 $4.98 7). The Company is also required to meet certain financial and other covenants in connection with the 2016 80% 1.25 1.00. $2,000,000, 1.25 1.00. March 31, 2017, In addition to all outstanding principal and accrued interest on the term loan, the Company shall pay a final payment fee equal to 4.00% All borrowings under the 2016 As of March 31, 2017, Year Ending December 31, 2017 $ 2,534 2018 4,463 2019 4,512 Total payments 11,509 Less: Amount representing interest (1,509 ) Present value of obligations 10,000 Less: Unamortized debt discount (336 ) 9,664 Less: Note payable, noncurrent portion 6,794 Note payable, current portion $ 2,870

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6. Operating Lease In January 2012, September 2016, March 2012 March 2018. three March 31, 2017 2016 $73,000 $55,000, On February 1, 2017, 12,400 January 26, 2017. second 2017 The term of the Sublease will commence on the later of (i) 120 tenant 36 may The monthly base rent under the Sublease will be equal to $20.50 first $21.12 21.75 second third $22,000. $88,000 tenant As of March 31, 2017, Year Ending December 31, 2017 (remaining 9 months) $ 393 2018 339 2019 265 2020 112 Total minimum lease payments $ 1,109 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding in considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may

Note 7 - Common Stock

Note 7 - Common Stock	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. On March 22, 2017, March 2017 8,625,000 $4.00 $34,500,000. $31,503,000. On June 17, 2016, June 2016 3,105,000 $5.00 $15,525,000. $13,886,000. Warrants for Common Stock As of March 31, 2017, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 91,532 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 425,274 In connection with the 2016 100,402 $4.98 $350,000, $90,000, three March 31, 2017 2016, $35,000 zero March 31, 2017, $336,000. No warrants were exercised during the three March 31, 2017. 6,250 September 30, 2014, three March 31, 2016. No shares issuable pursuant to warrants have been cancelled in 2017. 1,094 two October 2014 2016 The stock-based compensation expense related to warrants issued was zero $142,000 three March 31, 2017 2016,

Note 8 - Summary of Stock Optio

Note 8 - Summary of Stock Options	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8. Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards from three 2005 “2005 2006 “2006 2013 “2013 The 2005 March 31, 2017, 1,892 2005 2005 2005 2005 1,892 $116.29 0.48 The 2006 September 23, 2014 2006 2006 2006 38,378 $10.49 5.63 The 2013 2013 2013 may may may 2013 may 10 may four may 424(f) 10% 110% five On August 22, 2016, 2013 2013 first January, 2013 4% December 23, 2016, 2017 2013 523,209 2,000,000 2,523,209 January 1, 2017. March 31, 2017, 2013 2,093,944 308,995 $5.82 9.05 Activity under the 2005 2006 2013 Three Months Ended March 31, 2017 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 229,860 $ 4.46 Options exercised - $ - Options canceled (5,410 ) $ 6.38 Options outstanding, end of period 2,134,214 $ 6.00 8.98 $ 1,832,711 Vested and exercisable and expected to vest, end of period 1,980,152 $ 6.03 8.94 $ 1,692,844 Vested and exercisable, end of period 501,273 $ 7.06 8.05 $ 419,952 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of March 31, 2017. The options outstanding and exercisable as of March 31, 2017 Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding as of March 31, 2017 Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Number Exercisable as of March 31, 2017 Weighted Average Exercise Price $2.64 12,500 $ 2.64 8.12 5,990 $ 2.64 $3.68 - $3.76 79,376 $ 3.75 7.86 41,343 $ 3.75 $4.46 - $4.92 427,829 $ 4.62 8.83 121,211 $ 4.80 $5.22 595,034 $ 5.22 9.74 41,748 $ 5.22 $6.00 562,074 $ 6.00 8.70 176,563 $ 6.00 $6.24 - $6.40 129,267 $ 6.35 8.91 36,034 $ 6.35 $7.00 - $7.92 282,219 $ 7.71 9.22 32,469 $ 7.72 $9.92 38,135 $ 9.92 5.65 38,135 $ 9.92 $56.00 - $296.00 7,780 $ 83.66 0.58 7,780 $ 83.66 2,134,214 $ 6.00 8.98 501,273 $ 7.06 Restricted Stock Awards In January 2016, 39,494 2013 2015 $6.24 89 September 2016. one January 2017 39,405 In August 2016, 5,998 2013 $7.89 5,998 In September 2016, 25,000 $7.58 one 1/4 th March 31, 2017, 12,500 In November 2016, 6,544 2013 $5.91 6,544 The total number of shares pursuant to outstanding RSAs as of March 31, 2017 12,500 Stock-Based Compensation During the three March 31, 2017 2016, 229,860 129,267 $1.96 $3.56 no three March 31, 2017. 1,314 three March 31, 2016. three March 31, 2016 $2,000. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2017 2016 Expected term (in years) 5 5 Average volatility 48 % 66 % Risk-free interest rate 2.02 % 1.55 % Dividend yield 0 % 0 % During the three March 31, 2017 2016, no no three March 31, 2017 2016. Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three March 31, 2017 2016 Three Months Ended March 31, 2017 2016 Cost of revenue $ 3 $ - Research and development 51 21 Selling, general and administrative 318 167 Total $ 372 $ 188 As of March 31, 2017, $3,878,000. 3.14

Note 9 - Income Taxes

Note 9 - Income Taxes	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. No provision for income taxes has been recorded due to the net operating losses incurred from inception to date, for which no benefit has been recorded. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three March 31, 2017 2016. 2017 0%.

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. In June 2006, October 4, 2007. 300 March 31, 2017, 380 37,500 $2,025,000 $1,215,000 three March 31, 2017 2016, March 31, 2017 December 31, 2016 $665,000 $1,297,000,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products likely require clearance or approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required clearances or approvals or for the indications requested. If the Company was denied such clearances or approvals or if such clearances or approvals were delayed, it would have a material adverse effect on the Company’s financial results, financial position and future cash flows. The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval that it refers to as Geneveve™. Geneveve includes three third In the U.S., the Company sells its products primarily through a direct sales force to health care practitioners. Outside the U.S., the Company sells through an extensive network of distribution partners. During the three March 31, 2017, two 33% three March 31, 2016, three 86% 10% three March 31, 2017 2016.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not provide its customers with a right of return.
Customer Advance Payments, Policy [Policy Text Block]	Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to a one
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2017 2016,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Three Months Ended March 31, 2017 2016 Stock options to purchase common stock 2,134,214 1,131,768 Warrants to purchase common stock 425,274 401,446 Restricted common stock awards 12,500 -
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In May 2014, 2014 09, 606).” five December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 2015 14); 2016 08); 2016 10); 2016 10). May 2016, 2016 12, 606) May 2014. In July 2015, 2015 11, 2015 11”). 2015 11 first 2015 11 January 1, 2017 January 1, 2017, In February 2016, 2016 02, 842)”. December 15, 2018, In March 2016, 2016 09, 718): December 15, 2016, January 1, 2017 In August 2016, 2016 15, 230)”. zero December 15, 2017, We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 2 - Summary of Significa17

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2017 2016 Stock options to purchase common stock 2,134,214 1,131,768 Warrants to purchase common stock 425,274 401,446 Restricted common stock awards 12,500 -

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2017 2016 Accrued professional fees $ 1,026 $ 483 Accrued bonuses 275 1,102 Accrued payroll and other related expenses 364 389 Accrued sales and use tax 111 39 Accrued interest 67 65 Other accruals 244 108 Total accrued liabilities $ 2,087 $ 2,186

Note 5 - Note Payable (Tables)

Note 5 - Note Payable (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2017 $ 2,534 2018 4,463 2019 4,512 Total payments 11,509 Less: Amount representing interest (1,509 ) Present value of obligations 10,000 Less: Unamortized debt discount (336 ) 9,664 Less: Note payable, noncurrent portion 6,794 Note payable, current portion $ 2,870

Note 6 - Commitments and Cont20

Note 6 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2017 (remaining 9 months) $ 393 2018 339 2019 265 2020 112 Total minimum lease payments $ 1,109

Note 7 - Common Stock (Tables)

Note 7 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 91,532 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 425,274

Note 8 - Summary of Stock Opt22

Note 8 - Summary of Stock Options (Tables)	3 Months Ended
	Mar. 31, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Three Months Ended March 31, 2017 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 229,860 $ 4.46 Options exercised - $ - Options canceled (5,410 ) $ 6.38 Options outstanding, end of period 2,134,214 $ 6.00 8.98 $ 1,832,711 Vested and exercisable and expected to vest, end of period 1,980,152 $ 6.03 8.94 $ 1,692,844 Vested and exercisable, end of period 501,273 $ 7.06 8.05 $ 419,952
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding as of March 31, 2017 Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Number Exercisable as of March 31, 2017 Weighted Average Exercise Price $2.64 12,500 $ 2.64 8.12 5,990 $ 2.64 $3.68 - $3.76 79,376 $ 3.75 7.86 41,343 $ 3.75 $4.46 - $4.92 427,829 $ 4.62 8.83 121,211 $ 4.80 $5.22 595,034 $ 5.22 9.74 41,748 $ 5.22 $6.00 562,074 $ 6.00 8.70 176,563 $ 6.00 $6.24 - $6.40 129,267 $ 6.35 8.91 36,034 $ 6.35 $7.00 - $7.92 282,219 $ 7.71 9.22 32,469 $ 7.72 $9.92 38,135 $ 9.92 5.65 38,135 $ 9.92 $56.00 - $296.00 7,780 $ 83.66 0.58 7,780 $ 83.66 2,134,214 $ 6.00 8.98 501,273 $ 7.06
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2017 2016 Expected term (in years) 5 5 Average volatility 48 % 66 % Risk-free interest rate 2.02 % 1.55 % Dividend yield 0 % 0 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended March 31, 2017 2016 Cost of revenue $ 3 $ - Research and development 51 21 Selling, general and administrative 318 167 Total $ 372 $ 188

Note 1 - The Company and Basi23

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Mar. 22, 2017	Jun. 17, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	May 09, 2016
Proceeds from Issuance of Common Stock			$ 31,503,000
Common Stock, Par or Stated Value Per Share			$ 0.0001		$ 0.0001	$ 0.0001
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues	8,625,000
Share Price	$ 4
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 31,503,000
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues		3,105,000
Share Price		$ 5
Proceeds from Issuance of Common Stock		$ 15,525,000
Proceeds From Issuance of Common Stock, Net		$ 13,886,000

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Warranty Period	1 year
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Customers	2	3
Concentration Risk, Percentage	33.00%	86.00%

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	2,134,214	1,131,768
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	425,274	401,446
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	12,500	0

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued professional fees	$ 1,026	$ 483
Accrued bonuses	275	1,102
Accrued payroll and other related expenses	364	389
Accrued sales and use tax	111	39
Accrued interest	67	65
Other accruals	244	108
Total accrued liabilities	$ 2,087	$ 2,186	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 5 - Note Payable (Details

Note 5 - Note Payable (Details Textual) - USD ($)	Jun. 20, 2016	Mar. 31, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		425,274
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Warrant Term	10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,402	100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.98	$ 4.98
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount	$ 10,000,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments	30
Debt Instrument, Interest Rate, Effective Percentage		7.94%
Debt Instrument, Covenant, Actual Performance Revenue to Planned Revenue, Minimum, Percentage		80.00%
Debt Instrument, Covenant, Unrestricted Cash in Accounts to Indebtedness Ratio		1.25
Debt Instrument, Covenant, Minimum Unrestricted Cash in Accounts		$ 2,000,000
Debt Instrument, Fee, Percentage		4.00%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	7.40%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	6.96%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | First Tranche [Member]
Proceeds from Issuance of Long-term Debt	$ 7,500,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Second Tranche [Member]
Proceeds from Issuance of Long-term Debt	$ 2,500,000

Note 5 - Note Payable - Summary

Note 5 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	[1]
2,017	$ 2,534
2,018	4,463
2,019	4,512
Total payments	11,509
Less: Amount representing interest	(1,509)
Present value of obligations	10,000
Less: Unamortized debt discount	(336)
	9,664
Less: Note payable, noncurrent portion	6,794	$ 7,762
Note payable, current portion	$ 2,870	$ 1,867
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Commitments and Cont29

Note 6 - Commitments and Contingencies (Details Textual)	Feb. 01, 2017USD ($)a$ / item	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)
Operating Leases, Rent Expense | $		$ 73,000	$ 55,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | a	12,400
Operating Leases of Lessee, Period Following Delivery of Possession Triggering Commencement	120 days
Lessee, Operating Lease, Term of Contract	3 years
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / item	20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / item	21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / item	21.75
Security Deposit | $	$ 22,000
Operating Leases, Allowance for Certain Improvements | $	$ 88,000

Note 6 - Commitments and Cont30

Note 6 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2017USD ($)
2017 (remaining 9 months)	$ 393
2,018	339
2,019	265
2,020	112
Total minimum lease payments	$ 1,109

Note 7 - Common Stock (Details

Note 7 - Common Stock (Details Textual) - USD ($)	Mar. 22, 2017	Jun. 17, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 20, 2016
Proceeds from Issuance of Common Stock			$ 31,503,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			425,274
Class of Warrants or Rights, Exercises in Period			0	6,250
Allocated Share-based Compensation Expense			$ 372,000	$ 188,000
The 2016 Loan Agreement [Member]
Debt Issuance Costs, Net			$ 90,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4.98		$ 4.98
Warrants and Rights Outstanding					$ 350,000
Amortization of Debt Discount (Premium)			$ 35,000	$ 0
Unamortized Debt Issuance Expense			$ 336,000
Vendors and Contractors Warrants, October and November 2014 Issuance [Member]
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period			0	1,094
Distributor Warrants, March 2016 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6.08
Allocated Share-based Compensation Expense			$ 0	$ 142,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues	8,625,000
Share Price	$ 4
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 31,503,000
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues		3,105,000
Share Price		$ 5
Proceeds from Issuance of Common Stock		$ 15,525,000
Proceeds From Issuance of Common Stock, Net		$ 13,886,000

Note 7 - Common Stock - Summary

Note 7 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	3 Months Ended
	Mar. 31, 2017	Jun. 20, 2016
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	425,274
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	91,532
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.72
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.24
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	26,875
Distributor Warrants, March 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.08
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.74
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.98	$ 4.98
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	100,402	100,402

Note 8 - Summary of Stock Opt33

Note 8 - Summary of Stock Options (Details Textual) - USD ($)	Dec. 23, 2016	Aug. 22, 2016	Jan. 31, 2017	Nov. 30, 2016	Sep. 30, 2016	Aug. 31, 2016	Jan. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Dec. 31, 2016	Dec. 22, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number								2,134,214		2,134,214	1,909,764
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price								$ 6		$ 6	$ 6.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term								8 years 357 days			9 years 43 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								229,860
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value									$ 2,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options								$ 3,878,000		$ 3,878,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								3 years 51 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%	0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%
Two Thousand Five Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance								1,892		1,892
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number								1,892		1,892
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price								$ 116.29		$ 116.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term								175 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number								38,378		38,378
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price								$ 10.49		$ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term								5 years 229 days
The 2013 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance								308,995		308,995
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number								2,093,944		2,093,944
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price								$ 5.82		$ 5.82
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term								9 years 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum								10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent								110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	523,209
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,523,209											2,000,000
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								229,860	129,267
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value								$ 1.96	$ 3.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								0
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number								12,500		12,500
The 2013 Plan [Member] | Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							39,494
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 6.24
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period					89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			39,405
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				6,544		5,998
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 5.91		$ 7.89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				6,544		5,998
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 7.58
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period										12,500
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								5 years
The 2013 Plan [Member] | Quarterly [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%

Note 8 - Summary of Stock Opt34

Note 8 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Options outstanding, Shares (in shares)	1,909,764
Options outstanding, Weighted average exercise price (in dollars per share)	$ 6.19
Options outstanding, weighted average remaining contractual term (Year)	8 years 357 days	9 years 43 days
Options outstanding, Aggregate Intrinsic Value	$ 1,832,711,000	$ 211,396
Options granted, Shares (in shares)	229,860
Options granted, Weighted average exercise price (in dollars per share)	$ 4.46
Options exercised, Shares (in shares)
Options exercised, Weighted average exercise price (in dollars per share)
Options canceled, Shares (in shares)	(5,410)
Options canceled, Weighted average exercise price (in dollars per share)	$ 6.38
Options outstanding, Shares (in shares)	2,134,214	1,909,764
Options outstanding, Weighted average exercise priceod (in dollars per share)	$ 6	$ 6.19
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares)	1,980,152
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share)	$ 6.03
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 343 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value	$ 1,692,844,000
Vested and exercisable, end of period, Number Of Shares (in shares)	501,273
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share)	$ 7.06
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 18 days
Vested and exercisable, end of period, Aggregate Intrinsic Value	$ 419,952,000

Note 8 - Summary of Stock Opt35

Note 8 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Options outstanding, number (in shares) | shares	2,134,214
Options outstanding, weighted average exercise price (in dollars per share)	$ 6
Options outstanding, weighted average remaining contractual term (Year)	8 years 357 days
Options exercisable, number exercisable (in shares) | shares	501,273
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.06
Range One [Member]
Options outstanding, number (in shares) | shares	12,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.64
Options outstanding, weighted average remaining contractual term (Year)	8 years 43 days
Options exercisable, number exercisable (in shares) | shares	5,990
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Range Two [Member]
Options outstanding, number (in shares) | shares	79,376
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.75
Options outstanding, weighted average remaining contractual term (Year)	7 years 313 days
Options exercisable, number exercisable (in shares) | shares	41,343
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.75
Exercise price range, lower limit (in dollars per share)	3.68
Exercise price range, upper limit (in dollars per share)	$ 3.76
Range Three [Member]
Options outstanding, number (in shares) | shares	427,829
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.62
Options outstanding, weighted average remaining contractual term (Year)	8 years 302 days
Options exercisable, number exercisable (in shares) | shares	121,211
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.80
Exercise price range, lower limit (in dollars per share)	4.46
Exercise price range, upper limit (in dollars per share)	$ 4.92
Range Four [Member]
Options outstanding, number (in shares) | shares	595,034
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.22
Options outstanding, weighted average remaining contractual term (Year)	9 years 270 days
Options exercisable, number exercisable (in shares) | shares	41,748
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.22
Range Five [Member]
Options outstanding, number (in shares) | shares	562,074
Options outstanding, weighted average exercise price (in dollars per share)	$ 6
Options outstanding, weighted average remaining contractual term (Year)	8 years 255 days
Options exercisable, number exercisable (in shares) | shares	176,563
Options exercisable, weighted average exercise price (in dollars per share)	$ 6
Range Six [Member]
Options outstanding, number (in shares) | shares	129,267
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.35
Options outstanding, weighted average remaining contractual term (Year)	8 years 332 days
Options exercisable, number exercisable (in shares) | shares	36,034
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.35
Exercise price range, lower limit (in dollars per share)	6.24
Exercise price range, upper limit (in dollars per share)	$ 6.40
Range Seven [Member]
Options outstanding, number (in shares) | shares	282,219
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.71
Options outstanding, weighted average remaining contractual term (Year)	9 years 80 days
Options exercisable, number exercisable (in shares) | shares	32,469
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.72
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Range Eight [Member]
Options outstanding, number (in shares) | shares	38,135
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	5 years 237 days
Options exercisable, number exercisable (in shares) | shares	38,135
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92
Range Nine [Member]
Options outstanding, number (in shares) | shares	7,780
Options outstanding, weighted average exercise price (in dollars per share)	$ 83.66
Options outstanding, weighted average remaining contractual term (Year)	211 days
Options exercisable, number exercisable (in shares) | shares	7,780
Options exercisable, weighted average exercise price (in dollars per share)	$ 83.66
Exercise price range, lower limit (in dollars per share)	56
Exercise price range, upper limit (in dollars per share)	$ 296

Note 8 - Summary of Stock Opt36

Note 8 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Expected term (in years) (Year)	5 years	5 years
Average volatility	48.00%	66.00%
Risk-free interest rate	2.02%	1.55%
Dividend yield	0.00%	0.00%

Note 8 - Summary of Stock Opt37

Note 8 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Allocated share-based compensation expense	$ 372	$ 188
Cost of Sales [Member]
Allocated share-based compensation expense	3
Research and Development Expense [Member]
Allocated share-based compensation expense	51	21
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 318	$ 167

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent			0.00%

Note 10 - Related Party Trans39

Note 10 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	Oct. 04, 2007	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Stock Issued During Period, Shares, New Issues	37,500
Related Party Transaction, Amounts of Transaction		$ 2,025,000	$ 1,215,000
Accounts Payable, Related Parties, Current		$ 665,000		$ 1,297,000